The European Union should allow drug prices to rise to U.S. levels in order to attract investment, the bosses of two European ...

European drugmakers are urging the EU to allow higher medicine prices, warning that without stronger investment incentives, ...

SALES: The group's first-quarter sales should come at $13.00 billion, according to a consensus of analysts' estimates compiled by Visible Alpha. This compares with $11.83 billion the year before. In ...

In what could be seen as a bellwether for the pharmaceutical industry's sweeping shift toward localised manufacturing—spurred ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

CEOs from European drugmakers Sanofi and Novartis have inked a letter in The Financial Times urging the European Union to set ...

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

The pharmaceutical firm will establish a research innovation hub in California, and manufacturing facilities in Florida, ...

The so-called 'Most Favored Nations' rule would set drug pricing for Medicare in line with the prices paid by other nations, ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S.

Granite Bio is ready to rock 'n' roll, unveiling with $100 million and hopes of shaping new antibody treatments targeting ...

Novartis AG NVS, a Swiss pharma giant, is scheduled to report first-quarter 2025 results on April 29, 2025. The Zacks Consensus Estimate for revenues is pegged at $12.86 billion, while the same ...